immunology and endocrinology: https://www.researchgate. net/publication/270161648_Autoimmune_Syndromes_ Endocrine_Autoimmunity_Potpourri).
Profs. Cruse, Lewis, and I always had very informative and entertaining discussions until recently, when Prof. Cruse sadly passed away [19] [20] [21] [22] . Based on these intellectual interactions with these two wonderful colleagues I learned more about immunoendocrinology and in 2013, I had the honor to present a lecture at the Southern States Chapter of the American College of Endocrinologists (https://www.researchgate.net/publication/329124524_ When_Neuroendocrinology_and_Immunology_Meet_ Practical_Considerations), illustrating how the immune system controls endocrine organs and function and reviewing how sex steroids control neuro-inflammatory processes in the brain. As usual, caring for patients often makes me think about why people have certain afflictions. Acknowledging that Mississippi is one of the US states with the highest percentage of obese individuals, it is conceivable that persistent organic pollutants impact the immune system. Persistent organic pollutants have high lipid solubility and bioaccumulate in fatty tissues of not only animals but also humans (https://en.wikipedia.org/wiki/Persistent_ organic_pollutant). Furthermore, contamination of groundwater and drinking (tap) water with micropollutants and pharmaceuticals, including antibiotics, can impact health of animals and humans and their (intestinal) microbiome [23] [24] [25] [26] [27] .
Such an environmental impact can lead to molecular mimicry. In predisposed individuals, a microbial antigen would then trigger autoimmunity because of structural similarity to an autoantigen of the host [28] [29] [30] [31] [32] [33] [34] [35] [36] . Being born and growing up in such an obesogenic and polluted environment may be more challenging for changing the deleterious course on health than coming into such an environment from outside as an adult, although both situations will alter the gut microbiome [37] [38] [39] [40] [41] . The question arises when the time has come to act on limiting endocrine disrupting chemicals (https://www.researchgate.net/publication/ 292335196_Endocrine_Disruptors_is_it_time_to_act and https://www.researchgate.net/publication/270161477_ Endocrine_Aspects_in_Obesity_What_the_Non-Endocrinologist_Should_Know/download). The FDA has published pamphlets on how to dispose of unused medicines and the risks associated with the environmental release of pharmaceuticals on the United States FDA Bflush list^ [42] .
As a simple rule, in my opinion, one should read about the ancient Greek philosophers and their concept of the four elements, earth, fire, water, and air, and put that into contemporary context in hopes of identifying what people need to do to preserve life on the planet Earth (https://en.wikipedia.org/ wiki/Classical_element).
The complex interaction between environmental, hormonal, immune, and genetic factors has been coined as a Bmosaic of autoimmunity^ [43] . The autoimmune/ inflammatory syndrome is induced by adjuvants including aluminum and silicone. Medical conditions of this syndrome are vaccination-induced autoimmunity, silicone implants-induced autoimmunity, Gulf War syndrome, macrophagic myofasciitis with chronic fatigue syndrome, and the sick building syndrome [44] [45] [46] .
The presence of autoantibodies alone is not sufficient to define a disease as autoimmune. According to Whitebsky there also should be a demonstration of lymphocytic infiltration in the target organs, identification and characterization of auto-antigens, and induction of the disease in animal models with the injection of auto-antigens and passive transfer by serum or lymphocytes [47] . Interestingly, (only) approximately 30% of patients with stiff person syndrome develop diabetes mellitus, although auto-antibodies directed to the 65-kDa isoform of glutamic acid decarboxylase (GAD) are present [48] . In the TrialNet pathway to prevention study, 994 relatives with normal glucose tolerance and being positive for a single Bdiabetes^autoanti-body, were followed prospectively and tested for antibodies against islet cells, zinc transporter 8, insulin, insulinoma associated antigen 2, and GAD. After a median follow-up of 2 years, 141 relatives were found to have at least one additional autoantibody [49] . When comparing identical twins and full siblings in the TrialNet pathway to prevention study including 17,226 subjects, the risk of type 1 diabetes at 3 years was high (>69%) for identical twins who were positive for initially multiple and single Bdiabetes^auto-antibodies and for non-identical twins with multiple Bdiabetes^autoantibodies. For initially Bdiabetes^autoan-tibody negative identical twins, the risk of developing type 1 diabetes was 1.5% [50] .
Similarly, euthyroid individuals may have very high titers of antithyroid peroxidase antibodies [51] . Analyzing more than 16,000 individuals in the National Health and Nutrition Examination Survey (NHANES) revealed a prevalence of approximately 10% of people with anti-thyroglobulin antibodies and approximately 11% of subjects with antithyroperoxidase antibodies. Positivity for both antithyroidal antibodies increased the odds ratio of developing hypothyroidism from 6.9 (anti-thyroperoxidase antibody alone) to 23.5. The presence of anti-thyroglobulin antibody alone was not a risk factor of hypothyroidism. Interestingly, no anti-thyroid antibodies were detected in 31% of men and in 11% of women who had unequivocal elevations (> 10 mIU per liter) of thyroid stimulating hormone/TSH [https://www.thyroidmanager.org, 52, 53]. 1184 Western Australian subjects were followed for 13 years while checking serum concentrations of thyroid stimulating hormone (TSH) and antibodies directed to thyroid peroxidase and thyroglobulin. In 112 subjects, overt hypothyroidism developed. In women with positive antithyroidal antibodies, 55% became hypothyroid when the initial TSH was between 2.5 and 4.0 mU per Liter [54] .
Guest Editor Prof. Antonelli whose roots of endocrinology and immunology go back into the 1980's and I myself have met at one of the annual Endocrine Society meetings via introduction by Prof. Salvatore Benvenga who has also worked at the NIH in Bethesda, MD, in the past [55] [56] [57] [58] [59] [60] [61] . This guest issue begins with a review on the immune cell-adipocyte crosstalk as an important regulator not only of adipose tissue function, but also of systemic metabolism and homeostasis [62] . The group around Professor Chavakis has made major contributions on inflammasome pathways [63] . The second article will then focus on the role of microbiota in maintaining nutritional, metabolic, and immunologic homeostasis with an emphasis on thyroid autoimmunity [39] . Next will be a review of the increasing prevalence of chronic lymphocytic thyroiditis in papillary microcarcinoma. Hashimoto' s thyroiditis coexists in approximately one third of patients with papillary thyroid microcarcinoma [64] . At my present clinical practice location, I see many patients with autoimmune skin disorders referred by dermatologists. In particular, women with alopecia areata and/or totalis suffer from this appearance. Unfortunately, no universal therapy exists, although successful hair regrowth after certain immunotherapies, with ustekinumab, has been reported [65] [66] [67] . A retrospective study showed that 12 of 70 patients (17%) with alopecia totalis had complete hair regrowth but 30 patients with alopecia universalis (65%) remained in an alopecic state without improvement long term [68] . The epidemiology, clinical manifestations, and pathogenesis of the main autoimmune skin disorders such as alopecia, vitiligo, pemphigus, bullous pemphigoid, and their association with thyroid disease will be reviewed by Dr. Baldini and colleagues [69] , followed by a review on thyroid disorders induced by checkpoint inhibitors such as monoclonal antibodies directed to cytotoxic T lymphocyte-associated protein 4 (CTLA-4), programmed death receptor-1 (anti-PD-1), and programmed death-ligand 1 (anti-PD-L1) [8] . Checkpoint inhibitor therapy, especially with anti-CTLA-4, is also associated with hypophysitis [1] . Dr. Gubbi and colleagues from the NIH review the topic primary hypophysitis and other autoimmune disorders of the sellar and suprasellar regions with an emphasis on lymphocytic hypophysitis [70] .
Myoinositol is involved in intracellular thyroidstimulating hormone signaling, has immunomodulatory effects, and may be effective in protecting thyroid cells from reactive oxygen species such as hydrogen peroxide and pro-inflammatory cytokines which will be reviewed by the group around Prof. Antonelli [71, 72] .
Immunomodulatory effects can also be observed in/with many other substances and medications. The role of the peptide hormone somatostatin has been recently reviewed in an issue on neuroendocrine neoplasms, including its impact on the immune system [73] . Somatostatin receptor subtype 1 and subtype 2 are both expressed on fibroblast-like synovial cells and somatostatin analog therapy may be effective in treating patients with rheumatoid arthritis [74] . Of 175 patients with sarcoidosis, all but one patient showed uptake when undergoing somatostatin receptor scintigraphy. In 6% of these patients, exclusive extrapulmonary disease was identified [75] .
Besides their well established role in reducing cardiovascular risk, statins also exert immunomodulatory effects. This topic including statins, metformin, pro-proteinconvertase-subtilisin-kexin type-9 (PCSK9) inhibitors, angiotensin converting enzyme inhibitors and sex hormones will be reviewed by me with colleagues Dr. Hehmke and Prof. Krabbe, who have extensive experience with immunodiagnostics methods utilized at the Institute of Diabetes BGerhardt Katsch^in Karlsburg, Germany [76] . Statins are known to be associated with myopathy and many patients with muscle complaints have these complaints in the absence of prior statin use [77] . Myalgia is reported in approximately 9% of patients on atorvastatin and in approximately 5% of placebo patients when using self-reported symptoms and there have not been validated scales to diagnose statinassociated myalgia [77] . Interestingly, discontinuation of statin therapy for 2 weeks caused improvement in musculoskeletal symptoms in 75% of patients with statin-associated muscle side effects. After stopping initial statin therapy, 92% of patients are able to tolerate a second statin. A skeletal muscle biopsy is recommended for persistent tenderness and myalgia with moderate to severe elevations of creatine kinase. Major autoimmune myopathies include dermatomyositis, polymyositis, myositis associated with antisynthetase syndrome, inclusion body myositis, and immune-mediated necrotizing myopathy. Typically, glucocorticoisteroids are considered first-line therapy, although intravenous immunoglobulin has also been used, especially in patients with immune-mediated necrotizing myopathy related to statin use [78] . The detection of anti-3-hydroxy-3-methyl-glutaryl-coenzyme A reductase antibodies with prior or current statin use can assist in diagnosis and management, as timely treatment with immunosuppressive agents can increase the likelihood of a favorable outcome [77] . In an Australian population-based case-control study, using the South Australian Myositis Database, of all histologically confirmed cases of idiopathic inflammatory myositis and controls from the North West Adelaide Health Study, statin exposure at the time of diagnosing idiopathic inflammatory myositis occurred in 31% of patients and in 22% of matched controls [79] . This issue will be concluded by 2 articles related to infection with hepatitis C virus, one article by Dr. Colaci and colleagues, reviewing endocrine disorders in such patients and the final article, a systematic review and meta-analysis, by Prof. Antonelli and colleagues focusing on the development of diabetes mellitus [80, 81] .
As I conclude my term as the Editor-in-Chief of this journal, I wish to say farewell and thank the readership, guest editors, associate editors, Editorial Board, and the current and past Springer staff, especially Laura Walsh, Elizabeth Dziubela, Mitchelle Joseph, Rosario Gramatica, and John Rafael Patricio, for their support which has helped the journal maintain its excellent Impact Factor.
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